Business Context and Reporting Period
This Form 8-K Current Report was filed by AgeX Therapeutics, Inc. (trading symbol: AGE) on April 04, 2022. The registrant is a Delaware corporation headquartered in Alameda, California, and is classified as an emerging growth company. The report details a new debt financing transaction and the issuance of unregistered equity securities.
Key Financial Metrics and Transaction Details
- Debt Financing: AgeX borrowed an additional $1,000,000 under a Secured Convertible Promissory Note with Juvenescence Limited.
- Total Borrowed: The cumulative amount drawn under the line of credit is now $9,160,000.
- Remaining Capacity: Up to $4,000,000 remains available for future draws, subject to lender discretion and a $1,000,000 limit per single draw.
- Repayment Date: The outstanding principal is due on February 14, 2024.
- Cost of Capital: In lieu of accrued interest, the company pays an Origination Fee of 4% on each draw at funding, plus an additional 4% on the total drawn amount accruing after the 12-month draw period.
- Equity Issuance: In connection with the draw, AgeX issued warrants to purchase 568,440 shares of common stock at an exercise price of $0.8796 per share.
Material Changes Versus Prior Period
The filing does not provide comparative financial statements (revenue, profit, or cash flow) for the period. The material change reported is the increase in outstanding debt obligations and the dilution potential from the new warrant issuance compared to the prior state of the credit facility.
Guidance, Risks, and Contingencies
- Events of Default: The note contains extensive default provisions, including failure to pay principal or fees, breach of covenants, cross-defaults on other indebtedness exceeding $100,000, insolvency, and material asset dispositions exceeding $250,000.
- Acceleration: The entire outstanding amount may become immediately due upon an Event of Default.
- Forward-Looking Statements: The company disclaims any obligation to update forward-looking statements and warns that actual results may differ materially from anticipated results due to risk factors outlined in periodic reports.
- Liquidity: The transaction provides immediate liquidity but increases fixed obligations due in 2024.
Investor Verification Checklist
- Verify the total outstanding debt balance of $9,160,000 against the company's most recent 10-Q or 10-K filings.
- Confirm the listing status of the 568,440 warrants on the NYSE American.
- Review the "Risk Factors" section in the latest periodic report for details on the company's ability to service the debt maturing in February 2024.
- Assess the impact of the 8% total origination fee structure on the effective cost of capital.
- Check for any other indebtedness exceeding $100,000 that could trigger a cross-default under the new note terms.